^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    VEGF inhibitor

    Related drugs:
    1d
    A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma (clinicaltrials.gov)
    P2, N=132, Not yet recruiting, Akeso
    New P2 trial
    |
    Idafang (ivonescimab)
    2d
    Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC (clinicaltrials.gov)
    P2, N=120, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    6d
    Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abnormalities (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 overexpression • HER-2 amplification
    |
    Herceptin (trastuzumab) • trastuzumab rezetecan (SHR-A1811) • Idafang (ivonescimab)
    6d
    Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets (clinicaltrials.gov)
    P2, N=158, Not yet recruiting, European Organisation for Research and Treatment of Cancer - EORTC | Trial completion date: Oct 2031 --> Apr 2032 | Initiation date: Apr 2026 --> Nov 2026 | Trial primary completion date: Jan 2031 --> Jan 2032
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    carboplatin • albumin-bound paclitaxel • pemetrexed • Idafang (ivonescimab)
    7d
    Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P=N/A, N=80, Recruiting, Peking University People's Hospital | Active, not recruiting --> Recruiting
    Enrollment open • IO biomarker
    |
    Idafang (ivonescimab)
    7d
    A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=265, Not yet recruiting, Akeso
    New P1/2 trial
    |
    carboplatin • Idafang (ivonescimab)
    7d
    CR-001-101: A Phase 1/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of CR-001 in Adult Participants with Locally Advanced or Metastatic Solid Tumors (2025-523590-42-00)
    P1/2, N=44, Not yet recruiting, Crescent Biopharma Inc.
    New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation • ALK translocation
    8d
    A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=16, Recruiting, Memorial Sloan Kettering Cancer Center
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement
    |
    Tepmetko (tepotinib) • Idafang (ivonescimab)
    10d
    C6461006: Symbiotic-GU-06-A Study to Learn About the Study Medicine PF-08634404 Alone or In Combination With Enfortumab Vedotin in Adult Participants With Locally Advanced or Metastatic Urothelial Cancer. (2025-523523-21-00)
    P1/2, N=6, Not yet recruiting, Pfizer Inc.
    New P1/2 trial
    |
    Padcev (enfortumab vedotin-ejfv)
    12d
    First-line envafolimab plus recombinant human-endostatin in advanced non-small cell lung cancer with PD-L1 tumor proportion score ≥1% (Endouble): A multicenter, prospective, single-arm, phase 2 trial. (PubMed, Cancer)
    Envafolimab combined with Rh-endostatin demonstrated favorable efficacy and tolerable toxicity in patients with PD-L1-positive, advanced driver-gene negative NSCLC.
    P2 data • Journal • Tumor proportion score • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • MMP1 (Matrix metallopeptidase 1)
    |
    PD-L1 expression
    |
    Enweida (envafolimab) • Endostar (recombinant human endostatin)
    12d
    CVL006-T1003: Clinical Study of CVL006 Combination With 9MW2821 (clinicaltrials.gov)
    P1/2, N=108, Not yet recruiting, Convalife (Shanghai) Co., Ltd.
    New P1/2 trial
    |
    NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    bulumtatug fuvedotin (9MW2821)
    15d
    A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing） (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Sinocelltech Ltd.
    New P2 trial
    |
    EGFR positive
    |
    docetaxel